Glucagon-like Peptide-1 Receptor Agonists in Liver Transplant Recipients: A Retrospective Cohort Study
Early GLP1RA initiation in liver transplant recipients was associated with reduced mortality, hospitalizations, respiratory, and cardiorenal complications without compromising graft safety. These findings support GLP1RAs as a promising adjunct therapy, warranting prospective trials to confirm benefits in this high-risk population.
Authors
- Hesham Sheashaa
- David Simper
- Eric Steidley
- Hoang Nhat Pham (ORCID: https://orcid.org/0000-0001-8412-0082)
- Michele Barnhill (ORCID: https://orcid.org/0000-0001-9247-3400)
- Said Alsidawi (ORCID: https://orcid.org/0000-0001-8750-7880)
- B. Aqel
- E. Habib
- Rama Mouhaffel
- Amani Elshaer
- Steven J. Lester
- Chadi Ayoub
- Reza Arsanjani
- W. Ray Kim
- Juan M. Farina
- Mahmoud Abdelnabi
- Ramzi Ibrahim
Institutions
- Mayo Clinic (US)
- University of Arizona (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Transplantation Direct
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1097/txd.0000000000001932
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00